438 results on '"Tiedemann, Rodger"'
Search Results
2. Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
3. OA-25 MM B cells and pre-plasma cell progenitors are the cellular origin of MM disease relapse following effective therapy targeting plasma cells
4. Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras
5. Addition of Cyclophosphamide “On Demand” to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma—A Retrospective Review of a Single-center Experience
6. The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma.
7. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation
8. Data from Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma
9. Supplementary Data from Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma
10. Supplementary Data from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
11. Table S2 from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
12. Data from Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome
13. Supplementary Table 1 from Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome
14. Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression
15. Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
16. Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation
17. Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
18. Correction to “Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma”
19. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains
20. Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size
21. Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma
22. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation
23. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5
24. sciCNV: high-throughput paired profiling of transcriptomes and DNA copy number variations at single-cell resolution
25. OAB-010: Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers
26. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis
27. Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults
28. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
29. Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma
30. Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
31. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma
32. Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma
33. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-κB with antimyeloma activity in vitro and in vivo
34. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma
35. Tandem Transplantation in Myeloma Patients with High Risk Cytogenetics: A 10 Year Single-Centre Experience
36. Cyproheptadine displays preclinical activity in myeloma and leukemia
37. AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies
38. Getting to the root of the problem: the causes of relapse in multiple myeloma
39. Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution
40. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.
41. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains.
42. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents
43. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity
44. Simultaneous Profiling of DNA Copy Number Variations and Transcriptional Programs in Single Cells using RNA-seq
45. Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
46. Syngeneic transplants for multiple myeloma – a single center experience and review of the literature
47. sciCNV: high-throughput paired profiling of transcriptomes and DNA copy number variations at single-cell resolution.
48. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines
49. sciCNV: High-throughput paired profiling of transcriptomes and DNA copy number variations at single cell resolution
50. Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.